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Volume 60, Number 6 Patterson et al 1497aortic coverage and a history of previous cerebrovascular
disease was predictive of stroke. The occurrence of peripro-
cedural neurologic complications during TEVAR signiﬁ-
cantly increased the risk of all-cause mortality at midterm
follow-up, emphasizing the need to develop preventative
strategies. Revascularization of the LSA should be consid-
ered in all patients undergoing elective TEVAR for TAA
and on a case-by-case basis in patients undergoing urgent
surgery or surgery for dissection.
We acknowledge Debra Shaver and Lois Fisher of
Medtronic for providing the registry data and assisting
with the study.
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at www.jvascsurg.org.DISCUSSIONDr Jon Matsumura (Madison, Wisc). Can you tell us how the
left subclavian coverage was ascertained? Speciﬁcally, was it from a
case report form or was it a core lab review of images? How did
you treat classiﬁcation for partial coverage of the left subclavian
or coverage with a bare-metal spring?
Dr Benjamin O. Patterson. I think that as you’d be aware
from these sort of registries that the data are collected in different
formats depending on which registry it is. Most of them actuallyhad an entry for management of the left subclavian artery, and
we derived it from there. Otherwise, we derived it from looking
at which revascularization procedures were performed and what
the zone of coverage was. Where it was partially covered, we clas-
siﬁed these as covered. In terms of coverage with the bare metal
spring, we did not have that data speciﬁcally.
Dr Marc Schermerhorn (Boston, Mass). Are you sure you
haven’t missed any patients who may have had a revascularization
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had a stent graft put in? The stroke and death rate with revascular-
ization may be higher than your current estimate.
Dr Patterson.We do not have any data because they were all
patients that had a device inserted. And for our database then, I
identiﬁed the patients based on their stenting procedures, so I
can’t give any data regarding the rates of adverse events following
the revascularization itself.
Dr Thomas Lindsay (Toronto, Ontario, Canada). I noticed
that in your data you have got both the registry data as well as
the data from St George’s. I noticed some of your coauthors are
from Philadelphia. I wonder why you didn’t have any data from
them?
And secondly, this is all registry data, or did these people have
to meet inclusion criteria to be in the registry? We all understand
the difference between real world applicability of stent grafts and
that data which are derived from clinical trials. In many clinical tri-
als, the difﬁcult anatomy is all selected out, and in fact, registry data
may give a better set of data than what happens in the real world.
So can you comment, on the source of this data? Was it consecu-
tive patients that were enrolled in the registry or did they have to
meet certain clinical inclusion criteria? And were there differences
between those patients and the St George’s group, which may
reﬂect nonclinical trial enrollment?
Dr Patterson. I think that there are differences between the
various registries. For example, the high risk of the VALOR study
included patients with lots of comorbidities that were not ﬁt foropen repair. In general, the St George’s cohort had more comor-
bidities and there were more urgent cases than in the other regis-
tries. The set which most mirrored ours in terms of the patient
demographics was the Captivia set, which has all indications. We
basically took all of the patients that were involved in the registries
and pooled them. We did not apply any inclusion or exclusion
criteria to them per se.
Dr Sateesh Babu (Hawthorne, NY). What is the working hy-
pothesis for the stroke in these patients? Unless one can postulate
the vertebrobasilar territory ischemic events, it is difﬁcult to explain
strokes in these patients.
Dr Patterson.Well, it is difﬁcult to say. I think the ﬁrst thing
to point out is just looking at our regression analysis makes the
relationship quite clear. But we hypothesize that it is probably to
do with interruption of the collateral supply of the circle of Willis.
If one looks at the data from the asymptomatic carotid surgery
trial, there is actually a protective effect on contralateral stroke in
the group that underwent surgery when you compare it with the
controls. There was a three times higher rate of contralateral stroke
in that group adding weight to the collateralization theory.
Dr Robert Zwolak (Lebanon, NH). Is there any information
in the databases about the timing of the subclavian revasculariza-
tion with regard to the aortic repair?
Dr Patterson. There is some, but it was too incomplete really
to incorporate in our analysis. But there is some. We could do a
subgroup analysis, but there is not a great deal of that information
available.
